Yuan-Yuan Liu
Research Subjects
Yuan-Yuan Liu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ai-Li Wang
Center for Clinical Research and Translational Medicine, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Chen-Xi Zhao
Center for Clinical Research and Translational Medicine
1 shared publication - Hailong Liu
Center for Clinical Research and Translational Medicine, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication Mo-Bin Lin
Center for Clinical Research and Translational Medicine
1 shared publication- Xia Chen
Center for Clinical Research and Translational Medicine
1 shared publication - Xue Zhou
Center for Clinical Research and Translational Medicine
1 shared publication
Latest Publications
- Open Access
- 19 December 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-13
MiR-429 Involves in the Pathogenesis of Colorectal Cancer via Directly Targeting LATS2
Colorectal cancer (CRC) is a leading cause of cancer-related death around the world whose recurrence and metastasis rate is high. Due to the underlying unclear pathogenesis, it is hard so far to predict the tumorigenesis and prevent its recurrence. YAP/TAZ has been reported to be activated and functioned as a potential oncogene in multiple cancer types and proved to be essential for the carcinogenesis of most solid tumors. In the present study, we found that YAP/TAZ was markedly upregulated in CRC tissues comparing with the adjacent noncancerous tissues due to the downregulation of LATS2, the main upstream regulator. We further identified miR-429 as a direct regulator of LATS2-YAP/TAZ activation, suggesting that the miR-429-LATS2-YAP/TAZ might be novel effective diagnostic axis and therapeutic targets for CRC.
- 19 December 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-13
Open AccessMiR-429 Involves in the Pathogenesis of Colorectal Cancer via Directly Targeting LATS2
Colorectal cancer (CRC) is a leading cause of cancer-related death around the world whose recurrence and metastasis rate is high. Due to the underlying unclear pathogenesis, it is hard so far to predict the tumorigenesis and prevent its recurrence. YAP/TAZ has been reported to be activated and functioned as a potential oncogene in multiple cancer types and proved to be essential for the carcinogenesis of most solid tumors. In the present study, we found that YAP/TAZ was markedly upregulated in CRC tissues comparing with the adjacent noncancerous tissues due to the downregulation of LATS2, the main upstream regulator. We further identified miR-429 as a direct regulator of LATS2-YAP/TAZ activation, suggesting that the miR-429-LATS2-YAP/TAZ might be novel effective diagnostic axis and therapeutic targets for CRC.